View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Deals Analysis
April 26, 2021

Europe’s medical devices industry saw a drop of 14.71% in deal activity during March 2021

Europe’s medical devices industry saw a drop of 14.71% in deal activity during March 2021, when compared with the last 12-month average, led by Hologic’s $159m acquisition of Diagenode, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

 

A total of 29 medical devices industry deals worth $521.49m were announced for the region in March 2021, against the 12-month average of 34 deals.

Of all the deal types, M&A saw most activity in March 2021 with 15 transactions, representing a 51.7% share for the region.

In second place was venture financing with 13 deals, followed by private equity deals with one transactions, respectively capturing a 44.8% and 3.5% share of the overall deal activity for the month.

In terms of value of deals, M&A was the leading category in Europe’s medical devices industry with $369.59m, while venture financing and private equity deals totalled $101.9m and $50m, respectively.

Europe medical devices industry deals in March 2021: Top deals

The top five medical devices deals accounted for 85.3% of the overall value during March 2021.

The combined value of the top five medical devices deals stood at $444.58m, against the overall value of $521.49m recorded for the month.

The top five medical devices industry deals of March 2021 tracked by GlobalData were:

1) Hologic’s $159m acquisition of Diagenode

2) The $110m acquisition deal with Softhale by Sino Biopharmaceutical

3) DCC Healthcare’s $95.58m acquisition of Worner Medizinprodukte

4) The $50m private equity deal with MedAlliance by Citic Capital Partners

5) Foresite Capital Management, F-Prime, Lansdowne Partners and Oxford Sciences Innovation’s venture financing of Genomics for $30m.

Related Companies

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU